PPAR transcriptional activator complex polymorphisms and the promise of individualized therapy for heart failure

Heart Failure Reviews

Volumn 15, Issue 3, 2010, Pages 197-207

  Mistry, Neville F ^a   Cresci, Sharon ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiovascular disease; ERR; Peroxisome proliferator activated receptor; PGC 1; Pharmacogenetics; PPAR

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTROGEN RECEPTOR GAMMA; FENOFIBRATE; GLITAZONE DERIVATIVE; LOSARTAN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PIOGLITAZONE; PLACEBO; RAGAGLITAZAR; RETINOID X RECEPTOR ALPHA; ROSIGLITAZONE; UNCLASSIFIED DRUG; GLUCOSE; LIPID;

ACUTE CORONARY SYNDROME; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHY; DIET THERAPY; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOGENESIS; PHARMACOGENETICS; REVIEW; BLOOD; CARDIOMYOPATHY; GENETICS; HEART LEFT VENTRICLE HYPERTROPHY; METABOLISM; TRANSCRIPTION INITIATION;

CARDIOMYOPATHIES; GLUCOSE; HEART FAILURE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; LIPIDS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; RECEPTORS, ESTROGEN; TRANSCRIPTIONAL ACTIVATION;

EID: 77954649186     PISSN: 13824147     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10741-008-9114-x     Document Type: Review

References (97)

1. Berkenstam A, Gustafsson JA (2005) Nuclear receptors and their relevance to diseases related to lipid metabolism. Curr Opin Pharmacol 5:171-176. doi:10.1016/j.coph.2005.01.003 (Pubitemid 40378749)
2. Benoit G, Malewicz M, Perlmann T (2004) Digging deep into the pockets of orphan nuclear receptors: insights from structural studies. Trends Cell Biol 14:369-376. doi:10.1016/j.tcb.2004.05.007 (Pubitemid 38891706)
3. Nolte RT, Wisely GB, Westin S, Cobb JE, Lambert MH, Kurokawa R et al (1998) Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptorgamma. Nature 395:137-143. doi:10.1038/25931 (Pubitemid 28425645)
4. Zhu Y, Kan L, Qi C, Kanwar YS, Yeldandi AV, Rao MS et al (2000) Isolation and characterization of peroxisome proliferatoractivated receptor (PPAR) interacting protein (PRIP) as a coactivator for PPAR. J Biol Chem 275:13510-13516. doi:10.1074/jbc.275.18.13510 (Pubitemid 30257416)
5. Kliewer SA, Umesono K, Noonan DJ, Heyman RA, Evans RM (1992) Convergence of 9-cis retinoic acid and peroxisome proliferators signalling pathways through heterodimer formation of their receptors. Nature 358:771-774. doi:10.1038/358771a0
6. Qi C, Zhu Y, Reddy JK (2000) Peroxisome proliferator-activated receptors, coactivators, and downstream targets. Cell Biochem Biophys 32(Spring):187-204. doi:10.1385/CBB:32:1-3:187
7. Spiegelman BM, Puigserver P, Wu Z (2000) Regulation of adipogenesis and energy balance by PPARgamma and PGC-1. Int J Obes Relat Metab Disord 24(Suppl 4):S8-S10
8. Yu C, Markan K, Temple KA, Deplewski D, Brady MJ, Cohen RN (2005) The nuclear receptor corepressors NCoR and SMRT decrease peroxisome proliferator-activated receptor gamma transcriptional activity and repress 3T3-L1 adipogenesis. J Biol Chem 280:13600-13605. doi:10.1074/jbc.M409468200 (Pubitemid 40517253)
9. Krogsdam AM, Nielsen CA, Neve S, Holst D, Helledie T, Thomsen B et al (2002) Nuclear receptor corepressor-dependent repression of peroxisome- proliferator-activated receptor deltamediated transactivation. Biochem J 363:157-165. doi:10.1042/0264-6021:3630157 (Pubitemid 34280622)
10. Picard F, Kurtev M, Chung N, Topark-Ngarm A, Senawong T,Machado De oliveira R et al (2004) Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature 429:771-776. doi:10.1038/nature02583 (Pubitemid 38833129)
11. Westin S, Kurokawa R, Nolte RT, Wisely GB, McInerney EM, Rose DW et al (1998) Interactions controlling the assembly of nuclear-receptor heterodimers and co-activators. Nature 395:199-202. doi:10.1038/26040 (Pubitemid 28425662)
12. Lehman JJ, Barger PM, Kovacs A, Saffitz JE, Medeiros DM, Kelly DP (2000) Peroxisome proliferator-activated receptor gamma coactivator-1 promotes cardiac mitochondrial biogenesis. J Clin Invest 106:847-856. doi:10.1172/JCI10268
13. Huss JM, Kelly DP (2004) Nuclear receptor signaling and cardiac energetics. Circ Res 95:568-578. doi:10.1161/01.RES.0000 141774.29937.e3
14. Horard B, Vanacker JM (2003) Estrogen receptor-related receptors: orphan receptors desperately seeking a ligand. J Mol Endocrinol 31:349-357. doi:10.1677/jme.0.0310349 (Pubitemid 38054510)
15. Huss JM, Kopp RP, Kelly DP (2002) Peroxisome proliferatoractivated receptor coactivator-1alpha (PGC-1alpha) coactivates the cardiac-enriched nuclear receptors estrogen-related receptoralpha and - gamma. Identification of novel leucine-rich interaction motif within PGC-1alpha. J Biol Chem 277:40265-40274. doi: 10.1074/jbc.M206324200 (Pubitemid 35215598)
16. Schreiber SN, Knutti D, Brogli K, Uhlmann T, Kralli A (2003) The transcriptional coactivator PGC-1 regulates the expression and activity of the orphan nuclear receptor estrogen-related receptor alpha (ERRalpha). J Biol Chem 278:9013-9018. doi: 10.1074/jbc.M212923200 (Pubitemid 36800379)
17. Ichida M, Nemoto S, Finkel T (2002) Identification of a specific molecular repressor of the peroxisome proliferator-activated receptor gamma Coactivator-1 alpha (PGC-1alpha). J Biol Chem 277:50991-50995. doi:10.1074/jbc.M210262200 (Pubitemid 36042269)
18. Huss JM, Torra IP, Staels B, Giguere V, Kelly DP (2004) Estrogen-related receptor alpha directs peroxisome proliferatoractivated receptor alpha signaling in the transcriptional control of energy metabolism in cardiac and skeletal muscle. Mol Cell Biol 24:9079-9091. doi:10.1128/MCB.24.20.9079-9091.2004 (Pubitemid 39313912)
19. Dufour CR, Wilson BJ, Huss JM, Kelly DP, Alaynick WA, Downes M et al (2007) Genome-wide orchestration of cardiac functions by the orphan nuclear receptors ERR alpha and gamma. Cell Metab 5:345-356. doi:10.1016/j.cmet.2007.03. 007 (Pubitemid 46667756)
20. Dewald O, Sharma S, Adrogue J, Salazar R, Duerr GD, Crapo JD et al (2005) Downregulation of peroxisome proliferator-activated receptor-alpha gene expression in a mouse model of ischemic cardiomyopathy is dependent on reactive oxygen species and prevents lipotoxicity. Circulation 112:407-415. doi:10.1161/CIRCULATIONAHA.105.536318 (Pubitemid 41022083)
21. Sack MN, Rader TA, Park S, Bastin J, McCune SA, Kelly DP (1996) Fatty acid oxidation enzyme gene expression is downregulated in the failing heart. Circulation 94:2837-2842
22. Barger PM, Brandt JM, Leone TC, Weinheimer CJ, Kelly DP (2000) Deactivation of peroxisome proliferator-activated receptor-alpha during cardiac hypertrophic growth. J Clin Invest 105:1723-1730. doi:10.1172/JCI9056
23. Cheng L, Ding G, Qin Q, Huang Y, Lewis W, He N et al (2004) Cardiomyocyte-restricted peroxisome proliferator-activated receptor-delta deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy. Nat Med 10:1245-1250. doi: 10.1038/nm1116 (Pubitemid 39540443)
24. Planavila A, Rodriguez-Calvo R, Jove M, Michalik L, Wahli W, Laguna JC et al (2005) Peroxisome proliferator-activated receptor beta/delta activation inhibits hypertrophy in neonatal rat cardiomyocytes. Cardiovasc Res 65:832-841. doi:10.1016/j.cardiores. 2004.11.011
25. Jamshidi Y, Montgomery HE, Hense HW, Myerson SG, Torra IP, Staels B et al (2002) Peroxisome proliferator - activated receptor alpha gene regulates left ventricular growth in response to exercise and hypertension. Circulation 105:950-955. doi:10.1161/hc0802.104535 (Pubitemid 34184573)
26. Sher T, Yi HF, McBride OW, Gonzalez FJ (1993) cDNA cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferator activated receptor. Biochemistry 32:5598-5604. doi:10.1021/bi00072a015
27. Schunkert H, Hengstenberg C, Holmer SR, Broeckel U, Luchner A, Muscholl MW et al (1999) Lack of association between a polymorphism of the aldosterone synthase gene and left ventricular structure. Circulation 99:2255-2260
28. Razeghi P, Young ME, Alcorn JL, Moravec CS, Frazier OH, Taegtmeyer H (2001) Metabolic gene expression in fetal and failing human heart. Circulation 104:2923-2931. doi:10.1161/hc4901.100526
29. Ichihara S, Obata K, Yamada Y, Nagata K, Noda A, Ichihara G et al (2006) Attenuation of cardiac dysfunction by a PPAR-alpha agonist is associated with down-regulation of redox-regulated transcription factors. J Mol Cell Cardiol 41:318-329. doi: 10.1016/j.yjmcc.2006.05.013 (Pubitemid 44080222)
30. Brigadeau F, Gele P, Wibaux M, Marquie C, Martin-Nizard F, Torpier G et al (2007) The PPARalpha activator fenofibrate slows down the progression of the left ventricular dysfunction in porcine tachycardia-induced cardiomyopathy. J Cardiovasc Pharmacol 49:408-415. doi:10.1097/FJC.0b013e3180544540 (Pubitemid 47000316)
31. Schupp M, Kintscher U, Fielitz J, Thomas J, Pregla R, Hetzer R et al (2006) Cardiac PPARalpha expression in patients with dilated cardiomyopathy. Eur J Heart Fail 8:290-294. doi: 10.1016/j.ejheart.2005.09.003 (Pubitemid 43674490)
32. Ding G, Fu M, Qin Q, Lewis W, Kim HW, Fukai T et al (2007) Cardiac peroxisome proliferator-activated receptor gamma is essential in protecting cardiomyocytes from oxidative damage. Cardiovasc Res 76:269-279. doi:10.1016/j.cardiores.2007.06.027 (Pubitemid 350198591)
33. Mehrabi MR, Haslmayer P, Humpeler S, Strauss-Blasche G, Marktl W, Tamaddon F et al (2003) Quantitative analysis of peroxisome proliferator- activated receptor gamma (PPARgamma) expression in arteries and hearts of patients with ischaemic or dilated cardiomyopathy. Eur J Heart Fail 5:733-739. doi:10.1016/S1388-9842(03)00148-X (Pubitemid 38198060)
34. Finck BN, Kelly DP (2002) Peroxisome proliferator-activated receptor alpha (PPARalpha) signaling in the gene regulatory control of energy metabolism in the normal and diseased heart. J Mol Cell Cardiol 34:1249-1257. doi:10.1006/jmcc.2002.2061
35. Finck BN, Bernal-Mizrachi C, Han DH, Coleman T, Sambandam N, LaRiviere LL et al (2005) A potential link between muscle peroxisome proliferator-activated receptor-alpha signaling and obesity-related diabetes. Cell Metab 1:133-144. doi:10.1016/j.cmet.2005.01.006 (Pubitemid 43960595)
36. Finck BN, Lehman JJ, Leone TC, Welch MJ, Bennett MJ, Kovacs A et al (2002) The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J Clin Invest 109:121-130
37. Altshuler D, Hirschhorn JN, Klannemark M, Lindgren CM, Vohl MC, Nemesh J et al (2000) The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 26:76-80. doi:10.1038/79839
38. Andrulionyte L, Zacharova J, Chiasson JL, Laakso M (2004) Common polymorphisms of the PPAR-gamma2 (Pro12Ala) and PGC-1alpha (Gly482Ser) genes are associated with the conversion from impaired glucose tolerance to type 2 diabetes in the STOP-NIDDM trial. Diabetologia 47:2176-2184. doi:10.1007/s00125-004-1577-2 (Pubitemid 40174691)
39. Deeb SS, Fajas L, Nemoto M, Pihlajamaki J, Mykkanen L, Kuusisto J et al (1998) A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 20:284-287. doi:10.1038/3099 (Pubitemid 28507675)
40. Meshkani R, Taghikhani M, Larijani B, Bahrami Y, Khatami S, Khoshbin E et al (2007) Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma2 (PPARgamma-2) gene is associated with greater insulin sensitivity and decreased risk of type 2 diabetes in an Iranian population. Clin Chem Lab Med 45:477-482. doi:10.1515/CCLM.2007.095 (Pubitemid 46632216)
41. Nemoto M, Sasaki T, Deeb SS, Fujimoto WY, Tajima N (2002) Differential effect of PPARgamma2 variants in the development of type 2 diabetes between native Japanese and Japanese Americans. Diabetes Res Clin Pract 57:131-137. doi:10.1016/S0168-8227(02)00027-X (Pubitemid 34626452)
42. Tai ES, Corella D, urenberg-Yap M, Adiconis X, Chew SK, TanCE et al (2004) Differential effects of the C1431T and Pro12Ala PPARgamma gene variants on plasma lipids and diabetes risk in an Asian population. J Lipid Res 45:674-685. doi:10.1194/jlr. M300363-JLR200
43. Flavell DM, Ireland H, Stephens JW, Hawe E, Acharya J, Mather H et al (2005) Peroxisome proliferator-activated receptor alpha gene variation influences age of onset and progression of type 2 diabetes. Diabetes 54:582-586. doi:10.2337/diabetes.54.2.582
44. Kang ES, Park SY, Kim HJ, Kim CS, Ahn CW, Cha BS et al (2005) Effects of Pro12Ala polymorphism of peroxisome proliferator-activated receptor gamma2 gene on rosiglitazone response in type 2 diabetes. Clin Pharmacol Ther 78:202-208. doi:10.1016/j.clpt.2005.04.013 (Pubitemid 41112288)
45. Wolford JK, Yeatts KA, Dhanjal SK, Black MH, Xiang AH, Buchanan TA et al (2005) Sequence variation in PPARG may underlie differential response to troglitazone. Diabetes 54:3319-3325. doi:10.2337/diabetes.54.11.3319 (Pubitemid 43334389)
46. Hansen L, Ekstrom CT, Tabanera YP, Anant M, Wassermann K, Reinhardt RR (2006) The Pro12Ala variant of the PPARG gene is a risk factor for peroxisome proliferator-activated receptorgamma/alpha agonist-induced edema in type 2 diabetic patients. J Clin Endocrinol Metab 91:3446-3450. doi:10.1210/jc.2006- 0590 (Pubitemid 44402117)
47. Sambandam N, Morabito D, Wagg C, Finck BN, Kelly DP, Lopaschuk GD (2006) Chronic activation of PPARalpha is detrimental to cardiac recovery after ischemia. Am J Physiol Heart Circ Physiol 290:H87-H95. doi:10.1152/ajpheart. 00285.2005
48. Panagia M, Gibbons GF, Radda GK, Clarke K (2005) PPARalpha activation required for decreased glucose uptake and increased susceptibility to injury during ischemia. Am J Physiol Heart Circ Physiol 288:H2677-H2683. doi:10.1152/ajpheart. 00200.2004
49. Lygate CA, Hulbert K, Monfared M, Cole MA, Clarke K, NeubauerS (2003) The PPARgamma-activator rosiglitazone does not alter remodeling but increases mortality in rats post-myocardial infarction. Cardiovasc Res 58:632-637. doi:10.1016/S0008-6363(03)00289-X (Pubitemid 36700421)
50. Yue TL, Bao W, Gu JL, Cui J, Tao L, Ma XL et al (2005) Rosiglitazone treatment in Zucker diabetic Fatty rats is associated with ameliorated cardiac insulin resistance and protection from ischemia/reperfusion-induced myocardial injury. Diabetes 54:554-562. doi:10.2337/diabetes.54.2.554
51. Liu HR, Tao L, Gao E, Lopez BL, Christopher TA, Willette RN et al (2004) Anti-apoptotic effects of rosiglitazone in hypercholesterolemic rabbits subjected to myocardial ischemia and reperfusion. Cardiovasc Res 62:135-144. doi:10.1016/j.cardiores. 2003.12.027
52. Charbonnel B, Dormandy J, Erdmann E, Massi-Benedetti M, Skene A (2004) The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients. Diabetes Care 27:1647-1653. doi:10.2337/diacare.27.7.1647 (Pubitemid 38857439)
53. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK et al (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366:1279-1289. doi:10.1016/S0140-6736(05)67528-9 (Pubitemid 41416583)
54. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE (2007) Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. J Am Med Assoc 298:1180-1188. doi:10.1001/jama.298.10.1180 (Pubitemid 47403104)
55. Nissen SE, Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356:2457-2471. doi:10.1056/NEJMoa072761
56. Koskinen P, Manttari M, Manninen V, Huttunen JK, Heinonen OP, Frick MH (1992) Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 15:820-825. doi:10.2337/diacare.15.7.820
57. Flavell DM, Jamshidi Y, Hawe E, Pineda TI, Taskinen MR, Frick MH (2002) Peroxisome proliferator-activated receptor alpha gene variants influence progression of coronary atherosclerosis and risk of coronary artery disease. Circulation 105:1440-1445. doi: 10.1161/01.CIR.0000012145.80593.25 (Pubitemid 34263275)
58. Cresci S, Jones PG, Sucharov CC, Marsh S, Lanfear DE, Garsa A et al (2008) Interaction between PPARA genotype and β-Blocker treatment influences clinical outcomes following acute coronary syndromes. Pharmacogenetics 9(10):1403-1417. doi:10.2217/14622416.9.10.1403
59. Sapone A, Peters JM, Sakai S, Tomita S, Papiha SS, Dai R et al (2000) The human peroxisome proliferator-activated receptor alpha gene: identification and functional characterization of two natural allelic variants. Pharmacogenetics 10:321-333. doi: 10.1097/00008571-200006000-00006
60. Flavell DM, Pineda TI, Jamshidi Y, Evans D, Diamond JR, Elkeles RS et al (2000) Variation in the PPARalpha gene is associated with altered function in vitro and plasma lipid concentrations in Type II diabetic subjects. Diabetologia 43:673-680. doi:10.1007/s001250051357 (Pubitemid 30322086)
61. Vohl MC, Lepage P, Gaudet D, Brewer CG, Betard C, Perron P et al (2000) Molecular scanning of the human PPARa gene: association of the L162v mutation with hyperapobetalipoproteinemia. J Lipid Res 41:945-952
62. Tai ES, Demissie S, Cupples LA, Corella D, Wilson PW, Schaefer EJ et al (2002) Association between the PPARA L162 V polymorphism and plasma lipid levels the Framingham Offspring Study. Arterioscler Thromb Vasc Biol 22:805-810. doi:10.1161/01.ATV.0000012302.11991.42 (Pubitemid 34517793)
63. Tai ES, Corella D, Demissie S, Cupples LA, Coltell O, Schaefer EJ et al (2005) Polyunsaturated fatty acids interact with the PPARA-L162V polymorphism to affect plasma triglyceride and apolipoprotein C-III concentrations in the Framingham Heart Study. J Nutr 135:397-403
64. Pischon T, Pai JK, Manson JE, Hu FB, Rexrode KM, Hunter D et al (2005) Peroxisome proliferator-activated receptor-gamma2 P12A polymorphism and risk of coronary heart disease in US men and women. Arterioscler Thromb Vasc Biol 25:1654-1658. doi:10.1161/01.ATV.0000171993.78135.7e (Pubitemid 41098936)
65. Doney AS, Fischer B, Leese G, Morris AD, Palmer CN (2004) Cardiovascular risk in type 2 diabetes is associated with variation at the PPARG locus: a Go-DARTS study. Arterioscler Thromb Vasc Biol 24:2403-2407. doi:10.1161/01.ATV. 0000147897.57527.e4 (Pubitemid 39658049)
66. Ridker PM, Cook NR, Cheng S, Erlich HA, Lindpaintner K, Plutzky J et al (2003) Alanine for proline substitution in the peroxisome proliferator-activated receptor gamma-2 (PPARG2) gene and the risk of incident myocardial infarction. Arterioscler Thromb Vasc Biol 23:859-863. doi:10.1161/01.ATV.00000 68680.19521.34
67. (1989) Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. New Engl J Med 321:129-135
68. Meirhaeghe A, Fajas L, Helbecque N, Cottel D, Lebel P, Dallongeville J et al (1998) A genetic polymorphism of the peroxisome proliferator-activated receptor gamma gene influences plasma leptin levels in obese humans. Hum Mol Genet 7:435-440. doi:10.1093/hmg/7.3.435 (Pubitemid 28120633)
69. Wang XL, Oosterhof J, Duarte N (1999) Peroxisome proliferatoractivated receptor gamma C161-[T polymorphism and coronary artery disease. Cardiovasc Res 44:588-594. doi:10.1016/S0008-6363(99)00256-264
70. Al-Shali KZ, House AA, Hanley AJ, Khan HM, Harris SB, Zinman B et al (2004) Genetic variation in PPARG encoding peroxisome proliferator-activated receptor gamma associated with carotid atherosclerosis. Stroke 35:2036-2040. doi:10.1161/01.STR.0000138784.68159.a5 (Pubitemid 39129555)
71. Chao TH, Li YH, Chen JH, Wu HL, Shi GY, Liu PY et al (2004) The 161TT genotype in the exon 6 of the peroxisome-proliferator-activated receptor gamma gene is associated with premature acute myocardial infarction and increased lipid peroxidation in habitual heavy smokers. Clin Sci (London, England) 107:461-466. doi:10.1042/CS20040014 (Pubitemid 39506737)
72. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ et al (2005) Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia 48:2482-2485. doi:10.1007/s00125-005-0029-y (Pubitemid 41738211)
73. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ et al (2004) Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364:685-696. doi: 10.1016/S0140-6736(04)16895-5 (Pubitemid 39140624)
74. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC et al (2005) Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352:1425-1435. doi:10.1056/NEJMoa050461 (Pubitemid 40471450)
75. Shepherd J, Barter P, Carmena R, Deedwania P, Fruchart JC, Haffner S et al (2006) Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care 29:1220-1226. doi:10.2337/dc05-2465 (Pubitemid 44125913)
76. Waters DD, LaRosa JC, Barter P, Fruchart JC, Gotto AM Jr, Carter R et al (2006) Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) study. J Am Coll Cardiol 48:1793-1799. doi:10.1016/j.jacc.2006.07.041 (Pubitemid 44648630)
77. Steiner G (2005) A new perspective in the treatment of dyslipidemia: can fenofibrate offer unique benefits in the treatment of type 2 diabetes mellitus? Treat Endocrinol 4:311-317. doi: 10.2165/00024677-200504050-00004 (Pubitemid 43126998)
78. Steiner G (2000) Lipid intervention trials in diabetes. Diabetes Care 23(Suppl 2):B49-B53
79. Zelvyte I, Dominaitiene R, Crisby M, Janciauskiene S (2002) Modulation of inflammatory mediators and PPARgamma and NFkappaB expression by pravastatin in response to lipoproteins in human monocytes in vitro. Pharmacol Res 45:147-154. doi: 10.1006/phrs.2001.0922 (Pubitemid 35425654)
80. Inoue I, Goto S, Mizotani K, Awata T, Mastunaga T, Kawai S et al (2000) Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: reduction of MRNA levels for interleukin-1beta, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor alpha (PPARalpha) in primary endothelial cells. Life Sci 67:863-876. doi:10.1016/S0024-3205(00)00680-9 (Pubitemid 30491080)
81. Chen S, Tsybouleva N, Ballantyne CM, Gotto AM Jr, Marian AJ (2004) Effects of PPARalpha, gamma and delta haplotypes on plasma levels of lipids, severity and progression of coronary atherosclerosis and response to statin therapy in the lipoprotein coronary atherosclerosis study. Pharmacogenetics 14:61-71. doi: 10.1097/00008571-200401000-00007 (Pubitemid 38183963)
82. Arany Z, He H, Lin J, Hoyer K, Handschin C, Toka O et al (2005) Transcriptional coactivator PGC-1 alpha controls the energy state and contractile function of cardiac muscle. Cell Metab 1:259-271. doi:10.1016/j.cmet.2005.03.002 (Pubitemid 43960608)
83. Lehman JJ, Kelly DP (2002) Transcriptional activation of energy metabolic switches in the developing and hypertrophied heart. Clin Exp Pharmacol Physiol 29:339-345. doi:10.1046/j.1440-1681.2002.03655.x (Pubitemid 34227071)
84. Wang S, Fu C, Wang H, Shi Y, Xu X, Chen J et al (2007) Polymorphisms of the peroxisome proliferator-activated receptorgamma coactivator-1alpha gene are associated with hypertrophic cardiomyopathy and not with hypertension hypertrophy. Clin Chem Lab Med 45(8):962-967. doi:10.1515/CCLM.2007.189 (Pubitemid 47424854)
85. Ambye L, Rasmussen S, Fenger M, Jorgensen T, Borch-Johnsen K, Madsbad S et al (2005) Studies of the Gly482Ser polymorphism of the peroxisome proliferator-activated receptor gamma coactivator 1alpha (PGC-1alpha) gene in Danish subjects with the metabolic syndrome. Diabetes Res Clin Pract 67:175-179. doi: 10.1016/j.diabres.2004.06.013 (Pubitemid 40093028)
86. Michael LF, Wu Z, Cheatham RB, Puigserver P, Adelmant G, Lehman JJ et al (2001) Restoration of insulin-sensitive glucose transporter (GLUT4) gene expression in muscle cells by the transcriptional coactivator PGC-1. Proc Natil Acad Sci USA 98:3820-3825. doi:10.1073/pnas.061035098 (Pubitemid 32249855)
87. Yoon JC, Xu G, Deeney JT, Yang SN, Rhee J, Puigserver P et al (2003) Suppression of beta cell energy metabolism and insulin release by PGC-1alpha. Dev Cell 5:73-83. doi:10.1016/S1534-5807(03)00170-9 (Pubitemid 36827343)
88. Petrovic MG, Kunej T, Peterlin B, Dovc P, Petrovic D (2005) Gly482Ser polymorphism of the peroxisome proliferator-activated receptor-gamma coactivator-1 gene might be a risk factor for diabetic retinopathy in Slovene population (Caucasians) with type 2 diabetes and the Pro12Ala polymorphism of the PPARgamma gene is not. Diabetes/Metab Res Rev 21:470-474. doi: 10.1002/dmrr.546 (Pubitemid 41320659)
89. Kunej T, Globocnik PM, Dovc P, Peterlin B, Petrovic DA (2004) Gly482Ser polymorphism of the peroxisome proliferator-activated receptor-gamma coactivator-1 (PGC-1) gene is associated with type 2 diabetes in Caucasians. Folia Biol 50:157-158 1990.
90. Huss JM, Imahashi K, Dufour CR, Weinheimer CJ, Courtois M, Kovacs A et al (2007) The nuclear receptor ERRalpha is required for the bioenergetic and functional adaptation to cardiac pressure overload. Cell Metab 6:25-37. doi:10.1016/j.cmet.2007.06.005 (Pubitemid 46995780)
91. Alaynick WA, Kondo RP, Xie W, He W, Dufour CR, Downes M et al (2007) ERRgamma directs and maintains the transition to oxidative metabolism in the postnatal heart. Cell Metab 6:13-24. doi:10.1016/j.cmet.2007.06.007 (Pubitemid 46995781)
92. Pollak A, Rokach A, Blumenfeld A, Rosen LJ, Resnik L, Dresner PR (2004) Association of oestrogen receptor alpha gene polymorphism with the angiographic extent of coronary artery disease. Eur Heart J 25:240-245. doi:10.1016/j.ehj. 2003.10.028 (Pubitemid 38235161)
93. Kunnas TA, Laippala P, Penttila A, Lehtimaki T, Karhunen PJ (2000) Association of polymorphism of human alpha oestrogen receptor gene with coronary artery disease in men: a necropsy study. BMJ (Clinical Research Ed) 321:273-274. doi:10.1136/bmj.321.7256.273
94. Figtree GA, Kindmark A, Lind L, Grundberg E, Speller B, Robinson BG et al (2007) Novel estrogen receptor alpha promoter polymorphism increases ventricular hypertrophic response to hypertension. J Steroid Biochem Mol Biol 103:110-118. doi: 10.1016/j.jsbmb.2006.09.035 (Pubitemid 46149299)
95. Malmqvist K, Kahan T, Edner M, Held C, Hagg A, Lind L et al (2001) Regression of left ventricular hypertrophy in human hypertension with irbesartan. J Hypertens 19:1167-1176. doi: 10.1097/00004872-200106000-00023 (Pubitemid 32493652)
96. Peter I, Shearman AM, Vasan RS, Zucker DR, Schmid CH, Demissie S et al (2005) Association of estrogen receptor beta gene polymorphisms with left ventricular mass and wall thickness in women. Am J Hypertens 18:1388-1395. doi:10.1016/j.amjhyper.2005.05.023 (Pubitemid 41566663)
97. Nohara A, Kawashiri MA, Claudel T, Mizuno M, Tsuchida M, Takata M et al (2007) High frequency of a retinoid X receptor gamma gene variant in familial combined hyperlipidemia that associates with atherogenic dyslipidemia. Arterioscler Thromb Vasc Biol 27:923-928. doi:10.1161/01.ATV.0000258945.76141.8a (Pubitemid 46606726)